JAMA Oncol

SGLT2 inhibitors may delay hormone therapy failure in prostate cancer

January 14, 2026

In a Hong Kong target trial emulation of 14,223 men with prostate cancer on androgen deprivation therapy (ADT), use of SGLT2 inhibitors was associated with reduced risk of ADT failure (hazard ratio [HR], 0.63) and next-generation hormonal agent failure (HR, 0.44) over a median 66-month follow-up. Findings were consistent across sensitivity analyses, with no significant differences between dapagliflozin and empagliflozin.

Clinical takeaway: SGLT2 inhibitors may help delay hormone therapy failure in prostate cancer, warranting further prospective evaluation.

Source:

Shi R, et al. (2026, January 8). JAMA Oncol. Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy. https://pubmed.ncbi.nlm.nih.gov/41505116/